Agilent Technologies, Inc. (LON:0HAV)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 28.56B +18.4% |
| Revenue (ttm) | 5.33B +9.1% |
| Net Income | 1.04B +21.3% |
| EPS | 3.67 +22.7% |
| Shares Out | n/a |
| PE Ratio | 27.43 |
| Forward PE | 21.55 |
| Dividend | 0.75 (0.55%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 989 |
| Open | 132.00 |
| Previous Close | 136.61 |
| Day's Range | 132.00 - 136.51 |
| 52-Week Range | 107.66 - 161.56 |
| Beta | 1.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 27, 2026 |
About Agilent Technologies
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnosti... [Read more]
Financial Performance
In fiscal year 2025, Agilent Technologies's revenue was $6.95 billion, an increase of 6.73% compared to the previous year's $6.51 billion. Earnings were $1.30 billion, an increase of 1.09%.
Financial numbers in USD Financial StatementsNews
Agilent receives FDA approval for expanded use of PD-L1 IHC 22C3 pharmDx
The company states: “Agilent (A) Technologies announced that the FDA has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to…
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code...
Agilent price target raised to $155 from $145 at BofA
BofA analyst Michael Ryskin raised the firm’s price target on Agilent (A) to $155 from $145 and keeps a Buy rating on the shares. Diagnostic tools have rallied almost 10%…
Agilent assumed with a Peer Perform at Wolfe Research
Wolfe Research assumed coverage of Agilent (A) with a Peer Perform rating. The company’s most recent quarter was a “small speed up with more thematic good guys than bad”, its…
Agilent initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of Agilent (A) with a Peer Perform rating and $130-$140 price target range. The company’s most recent quarter was a “small speed up with more thematic…
Agilent price target raised to $155 from $153 at RBC Capital
RBC Capital raised the firm’s price target on Agilent (A) to $155 from $153 and keeps an Outperform rating on the shares after its Q2 earnings beat. Agilent exceeded Street…
Agilent price target raised to $155 from $147 at TD Cowen
TD Cowen raised the firm’s price target on Agilent (A) to $155 from $147 and keeps a Buy rating on the shares. The firm updated its model following strong Q2…
Agilent introduces OpenLab Sync lab execution system
Agilent (A) Technologies announced the introduction of OpenLab Sync, a new Lab Execution System that enables laboratories to digitally connect scientific workflows from method design through execution...
Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally conn...
Agilent price target raised to $158 from $156 at Baird
Baird raised the firm’s price target on Agilent (A) to $158 from $156 and keeps an Outperform rating on the shares. The firm updated its model following the announcement of…
Agilent upgraded to Buy at BofA after ‘solid’ beat in Q2
As previously reported, BofA upgraded Agilent (A) to Buy from Neutral with a price target of $145, down from $150, following what the firm calls a “solid” fiscal Q2 beat.
Agilent price target lowered to $160 from $165 at Wells Fargo
Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Agilent (A) to $160 from $165 and keeps an Overweight rating on the shares. The firm notes the company…
Agilent price target raised to $145 from $140 at Barclays
Barclays raised the firm’s price target on Agilent (A) to $145 from $140 and keeps an Overweight rating on the shares. The company reported a solid quarter with “plenty of…
Agilent upgraded to Buy from Neutral at BofA
BofA upgraded Agilent (A) to Buy from Neutral with a price target of $145, down from $150.
Agilent Technologies Earnings Call Transcript: Q2 2026
Q2 delivered strong revenue, margin, and EPS growth, exceeding guidance across all metrics. Robust performance was broad-based, with standout gains in diagnostics, advanced materials, and forensics, while operational improvements and innovation drove margin expansion and raised full-year guidance.
Agilent Technologies Slides: Q2 2026
Agilent Technologies has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 27, 2026.
Agilent Technologies Earnings release: Q2 2026
Agilent Technologies released its Q2 2026 earnings on May 27, 2026, summarizing the period's financial results.
Agilent Technologies Quarterly report: Q2 2026
Agilent Technologies has published its Q2 2026 quarterly earnings report on May 27, 2026.
Agilent reports Q2 EPS $1.49, consensus $1.41
Reports Q2 revenue $1.83B, consensus $1.80B. CEO Padraig McDonnell says: “It was an excellent second quarter for Agilent (A), with broad-based strength across key end markets, exceptional operational ...
Agilent raises 2026 profit forecast on strong demand for lab tools
Life sciences firm Agilent Technologies raised its 2026 adjusted profit forecast on Wednesday, anticipating strong demand for its medical tools and equipment used in lab research and diagnostic serv...
Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.83 billion for the second quarter ended April 30, 2026, represent...
Agilent Launches New GC Systems with GC Assist to Improve Laboratory Efficiency and Data Quality
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the new 8890B GC and 8860B GC with GC Assist. GC Assist is the new, advanced instrument intellig...
Agilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of a new multi-attribute method (MAM) workflow designed to help pharmaceutical and biopharmaceutic...
Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent 9500 Triple Quadrupole ICP-MS, a next-generation inductively coupled plasma mass spe...
Agilent Launches 1290 Infinity III Fluorescence Detector for Confident Trace Analysis at UHPLC Speed
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent 1290 Infinity III Fluorescence Detector (FLD), a new fluorescence detector designed ...